Thalia Therapeutics (LON:THAT – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported GBX (0.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Thalia Therapeutics Stock Down 1.9%
THAT stock opened at GBX 0.61 on Wednesday. Thalia Therapeutics has a one year low of GBX 0.40 and a one year high of GBX 0.95. The stock has a market cap of £10.89 million and a price-to-earnings ratio of -3.61.
Thalia Therapeutics Company Profile
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Featured Stories
- Five stocks we like better than Thalia Therapeutics
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
- 4 Stocks That Could Split Next—and Why Investors Are Watching
- Oura’s IPO Freeze Isn’t the Warning Sign It Looks Like
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
Receive News & Ratings for Thalia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thalia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
